Modern approaches to the treatment of metastatic gastric cancer

Metastatic gastric cancer remains a significant challenge in oncology, characterized by a poor prognosis, with a five-year survival rate of less than 5% under standard chemotherapy. Advances in understanding the molecular mechanisms of tumor growth have led to the development of targeted and immunotherapeutic strategies, significantly improving outcomes in specific patient subgroups. Modern management of metastatic gastric cancer requires the assessment of molecular markers such as HER2, MSI-H, CPS, and CLAUDIN 18.2, as well as the identification of special clinical scenarios, including oligometastatic disease.